Combined intraosseous bioplasty, meniscectomy may improve outcomes in patients with OA
Click Here to Manage Email Alerts
Key takeaways:
- Patients who underwent arthroscopic meniscectomy and intraosseous bioplasty experienced significant reductions in pain.
- Among 31 patients, 13% underwent conversion to arthroplasty postoperatively.
NEW ORLEANS — Results showed intraosseous bioplasty combined with arthroscopic meniscectomy may improve pain and outcome scores, as well as yield a low conversion rate to arthroplasty, in patients with mild to severe osteoarthritis.
Rajit Saluja, MD, FAAOS, and colleagues analyzed the clinical outcomes of 31 patients with moderate to severe OA who received an injection of bone marrow aspirate concentrate with demineralized bone matrix, also known as intraosseous bioplasty (IOPB), during arthroscopic meniscectomy and debridement. Researchers utilized VAS and WOMAC scores to evaluate patients postoperatively at 6 months, 1 year and at a minimum final follow-up of 2 years.
Saluja said patients had significant improvements in postoperative WOMAC and VAS scores at 6 months, 1 year and final follow-up. In addition, 13% of the overall patient population and 14% of patients with a Kellgren-Lawrence grade of 3 or 4 underwent conversion to arthroplasty.
“We need longer follow-up to see how long the benefit lasts and who are the ideal candidates for this procedure,” Saluja said. “We also don’t know how much success was derived from the meniscectomy and debridement alone. We’re also not sure what added benefit of the intra-articular injection of the bone marrow aspirate concentrate provides.”
Collapse
Saluja R, et al. Injecting bone marrow aspirate concentrate into bone marrow edema lesions provides excellent outcomes. Presented at: Arthroscopy Association of North America Annual Meeting; May 4-6, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts